SOURCE: SpeechSwitch, Inc.

September 08, 2010 12:15 ET

SpeechSwitch, Inc. (USOTC: SSWC) Cancer Drug Delivery System Progress Report

FLEMINGTON, NJ--(Marketwire - September 8, 2010) - Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today that the regulatory affairs and quality control consulting firm of Mark F. Schenk Consulting will be advising the Company and coordinating the FDA filing for the Company's proprietary cancer drug delivery system. The design has moved from demonstrator prototyping to production prototyping. Solid Works production engineering drawings will be prepared on the final production design, and new production prototypes will be used to run comparative tests with predicate devices. Once these tests are completed, Mr. Schenk estimated that about three weeks of consulting work would be necessary to complete the FDA 510k application. Under Federal Rules, the FDA will be obligated to respond within 90 days of filing. The Company now owns United States Issued Patent No. 7,637,889 B2 and other related pending patent applications. The target goal is to sell the patent rights and pending FDA application, along with design and other know how rather than self-manufacture. Pharma companies continue to express interest in acquiring rights from the Company after the FDA 510k application is filed and before it is approved. There are four different design variations and this first product focus is for single vial liquid delivery into IV systems utilizing the patented slide valve-bypass outlet features. 

Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. 

Contact Information

  • Contact:
    Ken Glynn
    908 788 0077